Overview
A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction
Status:
Active, not recruiting
Active, not recruiting
Trial end date:
2023-12-31
2023-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
The aim of this study is to assess whether increasing oral doses of Riociguat are safe and improve the well-being, symptoms and outcome in patients with pulmonary hypertension associated with left ventricular systolic dysfunctionPhase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
BayerTreatments:
Riociguat
Criteria
Inclusion Criteria:- Male and female patients with symptomatic pulmonary hypertension due to left
ventricular systolic dysfunction despite optimized heart failure therapy
Exclusion Criteria:
- Types of pulmonary hypertension other than group 2.1 of Dana Point Classification